Hypertension and menopause
https://doi.org/10.15829/1728-8800-2019-4-115-127
Abstract
The climacteric period (menopause) is one of the most important periods in a woman’s life, reflecting the natural extinction of the reproductive function. Current hormonal changes and developing menopausal disorders initiate the formation of pathological conditions that have a negative impact on both the health and expectancy of life and its quality. Cardiovascular diseases are one of the most common pathological conditions. Arterial hypertension (AH) is a key risk factor for the development of cardiovascular diseases, in different periods of menopause has various clinical and pathogenetic features that must be considered during treatment. Indapamide have pronounced antihypertensive effect, organ-protective properties and metabolic neutrality. It is drug of choice for mono- or combination therapy for women with hypertension during different periods of menopause. Effective antihypertensive and organ-protective action, metabolic neutrality and safety of nitrendipine use allow us to recommend this drug for combination therapy of hypertension in women in distant menopause.
The combination of indapamide and nitrendipine may be one of the most effective tools for hypertension treating in women in distant climacteric period.
About the Authors
O. D. Ostroumova
I.M. Sechenov First Moscow State Medical University; Russian Clinical and Research Center of Gerontology
Russian Federation
Moscow.
Russian Federation
Moscow.
I. V. Goloborodova
Moscow State University of Medicine and Dentistry
Russian Federation
Moscow.
Russian Federation
Moscow.
References
1. Van Dijk GM, Kavousi M, Troup J, et al. Health issues for menopausal women: The top 11 conditions have common solutions. Maturitas. 2015;80(1):24-30. doi:101016/j.maturitas.2014.09.013.
2. Shcherbakova EM. The world's population is estimated by the UN 2017 revision. Demoskop Weekly. 2017;735-6. (In Russ.)
3. United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects: The 2017 Revision, Key Findings and Advance. Tables. 2017, Working Paper No. ESA/P/WP/248. https://esa.un.org/unpd/Wpp/Publications/Files/WPP2017_KeyFindings.pdf (14 June 2019).
4. Glotko OL, Ivanova AM, Lyubova GA, et al. Women and men of Russia. Stat. sb. ZH56 Rosstat. M., 2018. р. 241. (In Russ.)
5. Pahomov AA, Ruhlyada NN, Bakina NN, et al. Psychophysiological features of women in menopause. Scientific-theoretical journal Uchenye zapiski universiteta imeni P. F. Lesgafta. 2011;10(80):159-63. (In Russ.)
6. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2012 update: A report from the American Heart Association. Circulation. 2012;125(1):е2-220. doi:10.1161/CIR.0b013e31823ac046.
7. Harlow SD, Gass M, Hall JE, et al. Executive summary of the stages of reproductive aging workshop + 10: Addressing the unfinished agenda of staging reproductive aging. Menopause. 2012;19(4):387-95. doi:10.1097/gme.0b013e31824d8f40.
8. Balan VE, Vihlyaeva EM, Zajdieva YаZ, et al. Menopausal syndrome (clinical presentation, diagnosis, prevention and hormone replacement therapy). M.: Medicina, 1996. р. 64. (In Russ.)
9. Vihlyaeva EM. Postmenopausal therapy. Effects on menopause related symptoms, the course of chronic diseases and quality of life. M.: MEDpress-inform, 2008. р. 448. (In Russ.)
10. Nedogoda SV, Barykina IN, Hripaeva VYu, et al. Metabolic disorders in postmenopausal women and methods for their correction. Lekarstvennyj vestnik. 2014;3(55):10-8. (In Russ.)
11. Serov VN, Mihajlova OI, Blinova TV. Basic principles for the prevention and treatment of postmenopausal osteoporosis. Russian Medical J. 2009;16(17):9-16. (In Russ.)
12. Stevenson JC. A woman's journey through the reproductive, transitional and postmenopausal periods of life: Impact on cardiovascular and musculo-skeletal risk and the role of estrogen replacement. Maturitas. 2011;70(2):197-205. doi:10.1016/j.maturitas.2011.05.017.
13. Henderson VW. Menopause, cognitive ageing and dementia: practice implications. Menopause International. 2009;15(1):41-4. doi:10.1258/mi.2009.009003.
14. Gonzalez M, Reyes R, Damas C, et al. Oestrogen receptor alpha and beta in female rat pituitary cells: an immunochemical study. Gen Comp Endocrinol. 2008;155(3):857-68. doi:10.1016/j.ygcen.2007.10.007.
15. Ilovajskaya IA, Mihajlova DS. The effect of estrogen on the functional state of the central nervous system. Bulletin of Reproductive Health. 2008;3-4:25-8. (In Russ.)
16. Sherwin BB, Henry JF. Brain aging modulates the neuroprotective effects of estrogen on selective aspects of cognition in women: a critical review. Front Neuroendocrinol. 2008;29(1):88-113. doi:10.1016/j.yfrne.2007.08.002.
17. Cardiovascular diseases. https://wwwwho.int/ru/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (29 April 2019).
18. Ageeva LI, Aleksandrova GA, Zajchenko NM, et al. Health care in Russia. 2017: Stat. sb. Rosstat. M., 2017. р. 170. (In Russ.).
19. Anichkov DA, Shostak NA, Zhuravleva AD. Menopause and cardiovascular risk. Rational Pharmacotherapy in Cardiology. 2005; 1 (1):37-42. (In Russ.)
20. Donato GB, Fuchs SC, Oppermann K, et al. Association between menopause status and central adiposity measured at different cutoffs of waist circumference and waist-to-hip ratio. Menopause. 2006; 13:280-5. doi:10.1097/01.gme.0000177907.32634.ae.
21. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab. 2003;88:2404-11. doi:10.1210/jc.2003-030242.
22. Spencer CP, Godsland IF, Stevenson JC. Is there a menopausal metabolic syndrome? Gynecol Endocrinol. 1997;11:341-355. doi:10.3109/09513599709152559.
23. Janssen I, Powell LH, Crawford S, et al. Menopause and the metabolic syndrome: the Study of Women's Health Across the Nation. Arch Intern Med. 2008;168(14):1568-75. doi:10.1001/archinte.168.14.1568.
24. Ford ES, Giles WH, Dietz WH. Prevalence of the Metabolic Syndrome Among US Adults. JAMA. 2002;287(3):356-9. doi:10.1001/jama.287.3.356.
25. Howard BV, Cowan LD, Go O, et al. Adverse effects of diabetes on multiple cardiovascular disease risk factors in women. Diabetes Care. 1998;21:1258-65. doi:10.2337/diacare.21.8.1258.
26. Barrett-Connor EL, Cohn B, Wingard D, et al. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? JAMA. 1991;265:627-31. doi:10.1001/jama.1991.03460050081025.
27. Wilson PW, Kannell WB, Silbershatz H, et al. Clustering of metabolic factors and coronary heart disease. Arch Intern Med. 1999;159:1104-9. doi: 10.1001/archinte.159.10.1104.
28. Forouzanfar MH, Liu P, Roth GA, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015. JAMA. 2017;317:165-82. doi:10.1001/jama.2016.19043.
29. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of rannisdomised drug trials in their epidemiological context. Lancet. 1990;335:827-38. doi:10.1016/0140-6736(90)90944-Z.
30. Staessen J, Ginocchio G, Thijs L, et al. Conventional and ambulatory blood pressure and menopause in a prospective population study. J Hum Hypertens. 1997;11:507-14. doi:10.1038/sj.jhh.1000476.
31. Wassertheil-Smoller S, Anderson G, Psaty BM, et al. Hypertension and its treatment in postmenopausal women: baseline data from Women's Health Initiative. Hypertension. 2000:36:780-9. doi:10.1161/01.HYP.36.5.780.
32. Podzolkov VI, Bragina AE, Radionova VN, et al. Central and humoral mechanisms for arterial hypertension in women. Systemic Hypertension. 2015;1:76-82. (In Russ.)
33. Podzolkov VI, Bragina AE. Essential arterial hypertension in women or female arterial hypertension. Cardiovascular Therapy and Prevention. 2012;11(1):79-84. (In Russ.)
34. Yureneva SV, Il'ina LM, Smetnik VP. Female reproductive system aging: from theory to clinical practice. Part 1. The endocrine and clinical characteristics of female 50. reproductive system aging stages. Obstetrics and gynecology. 2014;3:21-7. (In Russ.)
35. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Womens Health Initiative Investigators. Risks and benefits of estrogen plus progestin in 52. healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-33. doi:10.1001/jama.288.3.321.
36. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021-104. doi:10.1093/eurheartj/ehy339.
37. Maslova NP, Baranova EI. Hypertensive disease in women. SPb.: SPbGMU, 2000. р. 214. (In Russ.)
38. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs-overview and meta-analyses. J Hypertens. 2015;33:195-211. doi: 101097/HJH.0000000000000378.
39. Roush GC, Ernst ME, Kostis JB, et al. Head-to-Head Comparisons of Hydrochlorothiazide With Indapamide and Chlorthalidone: Antihypertensive and Metabolic Effects. Hypertension. 2015;65(5):1041-6. doi:10.1161/hypertensionaha.114.05021.
40. Senior R, Imbs JL, Bory M, et al. Indapamide reduces hypertensive left ventricular hypertrophy: an international multimscenter study. J Cardiovasc Pharmacol. 1993;22(6):106-10.
41. PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J (Engl). 1995;108:710-7.
42. Karpov RS, Mordovin VF. Chronic forms of cerebrovascular disease in patients with arterial hypertension: frequency of detection, developmental dynamics, features of therapy. Consilium medicum. Diseases of the heart and blood vessels. 2006;3(1):17-21. (In Russ.)
43. PROGRESS Collaborative Group. Randomised trial of a perindoprilbased blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-41. doi:101016/S0140-6736(01)06178-5.
44. Donnelly R, Molyneaux LM, Willey KA, et al. Comparative effects of indapamide and captopril on blood pressure and albumin excretion rate in diabetic microalbuminuria. The Am J Cardiology. 1996;77(6):B26-30. doi:10.1016/s0002-9149(97)89237-5.
45. Sassard J, Bataillard A, McIntyre H. An overview of the pharmacology and clinical efficacy of indapamide sustained release. Fundam Clin Pharmacol. 2005;19:637-45. doi:10.1111/j.1472-8206.2005.00377.x.
46. Roush GC, Fagard RH, Salles GF, et al. Prognostic impact from clinic, daytime, and nighttime systolic blood pressure in 9 cohorts of 13 844 patients with hypertension. J Hypertens. 2014;32:2332-40. doi:10.1097/HJH.0000000000000355.
47. Roush GC, Fapohunda J, Kostis JB. Evening dosing of antihypertensive therapy to reduce cardiovascular events: a third type of evidence based on a systematic review and meta-analysis of randomized trials. J Clin Hypertens (Greenwich). 2014;16:561-8. doi:10.1111/jch.12354.
48. Hermida RC, Ayala DE, Mojon A, еt al. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int. 2010;27:1629-51. doi:10.3109/07420528.2010.510230.
49. Aubert I, Djian F, Rouffy J. Beneficial effects of indapamide on lipoproteins and apoproteins in ambulatory hypertensive patients. Am J Cardiol. 1990;65:77H-80. doi:10.1016/0002-9149(90)90349-6.
50. Mychka VB, Chazova IE. Russian evidence-based medicine — the MINOTAVR program. Consilium Medicum. 2006;5(8):46-50. (In Russ.)
51. Witchitz S, Kamoun A, Chiche P. A double-blind study in hypertensive patients of an original new compound, indapamide. Curr Med Res Opin. 1975;3:1-8. doi:10.1185/03007997509113637.
52. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl JMed. 2008;358:1887-98. doi:10.1056/nejmoa0801369.
53. Chukaeva II, Shurgaya MA. Features of the therapy of arterial hypertension in menopausal women. Diseases of the heart and blood vessels. 2006;2(2):29-32. (In Russ.)
54. Staessen JA, Thijs L, Fagard RH, et al. Calcium Channel Blockade and Cardiovascular Prognosis in the European Trial on Isolated Systolic Hypertension. Hypertension. 1998;32(3):410-6. doi:10.1161/01.hyp.32.3.410.
55. Tuomilehto J, Rastenyte D, Birkenhager WH, et al. For the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med. 1999;340:677-84. doi:10.1056/NEJM199903043400902.
56. Wang JG, Staessen JA, Gong L, et al. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med. 2000;160(2):211-20. doi:10.1001/archinte.160.2.211.
57. Safar M, Thijs L, Staessen JA. Syst-Eur study: analysis of the benefits of nitrendipine in hypertensive type 2 diabetics. Arch Mal Coeur Vaiss. 2003;96(7-8):768-71. PMID:12945220.
58. Modena MG, Mattioli AV, Parato VM, et al. Effect of antihypertensive treatment with nitrendipine on left ventricular mass and diastolic filling in patients with mild to moderate hypertension. J Cardiovasc Pharmacol. 1992;19(1):148-53.
59. Matsumoto M, Deng YB, Munehira J, et al. Effects of nitrendipine on left ventricular structure and function and aortic distensibility in elderly patients with isolated systolic hypertension. Curr Ther Res Clin Exp. 1997;58(2):117-26. doi:101016/S0011-393X(97)80121-X.
60. Voyaki SM, Staessen JA, Thijs L, et al. Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. J Hypertens. 2001;19(3):511-9. doi:10.1097/00004872-200103000-00020.
61. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. The Lancet.1998;352(9137):1347-51. doi:10.1016/s0140-6736(98)03086-4.
62. Trompet S, Westendorp R, Kamper A, et al. Use of calcium antagonists and cognitive decline in old age. The Leiden 85-plus study. Neurobiol Aging. 2008;29:306-8. doi:10.1016/j.neurobiolaging.2006.10.006.
63. Mancini M, Marotta T, Ferrara LA. Metabolic neutrality in nitrendipine therapy. J Cardiovasc Pharmacol. 1991;1:30-3. PMID:1723452.
64. Paolisso G, Aceto E, Cennamo G, et al. Metabolic effects of nitrendipine. Clin Ther. 1991;13(6):695-8. PMID:1790544.
65. Vanov SK, Pun EF, Taylor RJ. The safety of nitrendipine in the treatment of essential hypertension-a review of 61 clinical studies. Angiology. 1988;39(1):113-22. PMID:3277492.
66. Grandinetti O, Feraco E. Middle term evaluation of amlodipine vs. nitrendipine: efficacy, safety and metabolic effects in elderly hypertensive patients. Clinical and experimental hypertension. 1993;15(1):197-210. PMID:8513310.
Review
For citations:
Ostroumova O.D., Goloborodova I.V. Hypertension and menopause. Cardiovascular Therapy and Prevention. 2019;18(4):115-127. (In Russ.) https://doi.org/10.15829/1728-8800-2019-4-115-127
Views:
1269
Email this article 
